SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 5.4 Revision Date: 10/10/2020
SDS Number: 437334-00012 Date of last issue: 03/23/2020
Date of first issue: 01/28/2016

SECTION 1. IDENTIFICATION

Product name : Mometasone Dry Powder Inhaler Formulation

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATAPREVENT@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Combustible dust
Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Inhalation) : Category 2 (Immune system, Liver, Kidney, Skin)

GHS label elements
Hazard pictograms

Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H360Df May damage the unborn child. Suspected of damaging fertility.
H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Precautionary Statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 5.4  Revision Date: 10/10/2020  SDS Number: 437334-00012  Date of last issue: 03/23/2020
Date of first issue: 01/28/2016

Response:
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. Suspected of damaging fertility.
May cause damage to organs through prolonged or repeated exposure if inhaled.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO2)
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
 Chlorine compounds

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
 Use water spray to cool unopened containers.
 Remove undamaged containers from fire area if it is safe to do so.
 Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
 Prevent further leakage or spillage if safe to do so.
 Retain and dispose of contaminated wash water.
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

3 / 16
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents, Organic peroxides, Explosives, Gases.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td>Wipe limit 10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection: General and local exhaust ventilation is recommended to
SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 5.4  Revision Date: 10/10/2020  SDS Number: 437334-00012  Date of last issue: 03/23/2020  Date of first issue: 01/28/2016

Maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Eye protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Powder
Color: White
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
**SAFETY DATA SHEET**

**Mometasone Dry Powder Inhaler Formulation**

**Version** 5.4  
**Revision Date:** 10/10/2020  
**SDS Number:** 437334-00012  
**Date of last issue:** 03/23/2020  
**Date of first issue:** 01/28/2016

- **Flash point:** Not applicable
- **Evaporation rate:** No data available
- **Flammability (solid, gas):** May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids):** No data available
- **Upper explosion limit / Upper flammability limit:** No data available
- **Lower explosion limit / Lower flammability limit:** No data available
- **Vapor pressure:** No data available
- **Relative vapor density:** No data available
- **Density:** No data available
- **Solubility(ies):**  
  - **Water solubility:** No data available
- **Partition coefficient: n-octanol/water:** No data available
- **Autoignition temperature:** No data available
- **Decomposition temperature:** No data available
- **Viscosity:**  
  - **Viscosity, kinematic:** No data available
- **Explosive properties:** Not explosive
- **Oxidizing properties:** The substance or mixture is not classified as oxidizing.
- **Molecular weight:** No data available
- **Particle size:** No data available

**SECTION 10. STABILITY AND REACTIVITY**

- **Reactivity:** Not classified as a reactivity hazard.
- **Chemical stability:** Stable under normal conditions.
- **Possibility of hazardous reactions:**  
  - May form explosive dust-air mixture during processing, handling or other means.  
  - Can react with strong oxidizing agents.
- **Conditions to avoid:** Heat, flames and sparks.
Avoid dust formation.

Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Mometasone:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration): LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:

Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Mometasone:
Species: Rabbit
Result: No eye irritation
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Mometasone:
<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximization Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Dermal</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Assessment</td>
<td>Does not cause skin sensitization.</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity
Not classified based on available information.

Components:

Mometasone:
Genotoxicity in vitro:
<table>
<thead>
<tr>
<th>Test Type</th>
<th>Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo:
<table>
<thead>
<tr>
<th>Test Type</th>
<th>Micronucleus test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity -
Weight of evidence does not support classification as a germ
Assessment cell mutagen.

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Mometasone:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Route:</strong></td>
<td>Inhalation</td>
</tr>
<tr>
<td><strong>Exposure time:</strong></td>
<td>2 Years</td>
</tr>
<tr>
<td><strong>Dose:</strong></td>
<td>0.067 mg/kg body weight</td>
</tr>
<tr>
<td><strong>Result:</strong></td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Route:</strong></td>
<td>Inhalation</td>
</tr>
<tr>
<td><strong>Exposure time:</strong></td>
<td>19 Months</td>
</tr>
<tr>
<td><strong>Dose:</strong></td>
<td>0.160 mg/kg body weight</td>
</tr>
<tr>
<td><strong>Result:</strong></td>
<td>negative</td>
</tr>
</tbody>
</table>

**IARC**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

**NTP**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**
May damage the unborn child. Suspected of damaging fertility.

**Components:**

**Mometasone:**

**Effects on fertility**

<table>
<thead>
<tr>
<th><strong>Test Type:</strong></th>
<th>Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species:</strong></td>
<td>Rat</td>
</tr>
<tr>
<td><strong>Application Route:</strong></td>
<td>Subcutaneous</td>
</tr>
<tr>
<td><strong>Fertility:</strong></td>
<td>NOAEL: 0.015 mg/kg body weight</td>
</tr>
<tr>
<td><strong>Symptoms:</strong></td>
<td>Reduced embryonic survival, Reduced fetal weight</td>
</tr>
<tr>
<td><strong>Result:</strong></td>
<td>No effects on fertility, Effect on reproduction capacity</td>
</tr>
</tbody>
</table>

**Effects on fetal development**

<table>
<thead>
<tr>
<th><strong>Test Type:</strong></th>
<th>Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species:</strong></td>
<td>Mouse</td>
</tr>
<tr>
<td><strong>Application Route:</strong></td>
<td>Subcutaneous</td>
</tr>
<tr>
<td><strong>Embryo-fetal toxicity:</strong></td>
<td>LOAEL: 0.06 mg/kg body weight</td>
</tr>
<tr>
<td><strong>Result:</strong></td>
<td>Embryotoxic effects, Teratogenicity and developmental toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Test Type:</strong></th>
<th>Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species:</strong></td>
<td>Rat</td>
</tr>
<tr>
<td><strong>Application Route:</strong></td>
<td>Dermal</td>
</tr>
<tr>
<td><strong>Embryo-fetal toxicity:</strong></td>
<td>LOAEL: 0.3 mg/kg body weight</td>
</tr>
</tbody>
</table>
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Dermal
Embryo-fetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Embryo-fetal toxicity, Malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Subcutaneous
Embryo-fetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-fetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments, Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure
Not classified based on available information.

Components:
Mometasone:
Remarks: Based on available data, the classification criteria are not met.

STOT-repeated exposure
May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Components:
Mometasone:
Routes of exposure: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:
Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: Inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: Inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:

Mometasone:
Not applicable

Experience with human exposure

Components:

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Mometasone:
Toxicity to fish: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Persistence and degradability

Components:

Mometasone:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314
Stability in water: Hydrolysis: 50 %(12 d)
   Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
   Bioconcentration factor (BCF): 107.1
   Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.68

Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: log Koc: 4.02

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
   (Mometasone)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s.
   (Mometasone)
Class: 9
Packing group: III
Labels: Miscellaneous
SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 5.4

Revision Date: 10/10/2020
SDS Number: 437334-00012
Date of last issue: 03/23/2020
Date of first issue: 01/28/2016

Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)

Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class: 9
Packing group: III
Labels: CLASS 9
ERG Code: 171
Marine pollutant: yes(Mometasone)
Remarks: Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Combustible dust
Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
</tr>
</tbody>
</table>

The ingredients of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information

**NFPA 704:**

<table>
<thead>
<tr>
<th>Health</th>
<th>Flammability</th>
<th>Instability</th>
<th>Special hazard</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**HMIS® IV:**

- HEALTH: *
- FLAMMABILITY: 3
- PHYSICAL HAZARD: 0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the """" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

Revision Date: 10/10/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.